Bio Spec Overview
Ignite Creation Date:
2026-03-26 @ 3:17 PM
Last Modification Date:
2026-03-26 @ 3:17 PM
Retention:
SAMPLES_WITH_DNA
Description:
Peripheral blood samples will be collected at two predefined time points: prior to initiation of neoadjuvant chemotherapy and once between 1-6 months after radical nephroureterectomy.
Plasma-derived circulating tumor DNA (ctDNA) will be analyzed using whole-genome sequencing-based copy number variation assessment to estimate tumor fraction.
Biospecimens are collected for research purposes only and will not be used to guide clinical decision-making.
Samples may be stored for future translational analyses related to recurrence monitoring and molecular characterization of upper tract urothelial carcinoma.
Plasma-derived circulating tumor DNA (ctDNA) will be analyzed using whole-genome sequencing-based copy number variation assessment to estimate tumor fraction.
Biospecimens are collected for research purposes only and will not be used to guide clinical decision-making.
Samples may be stored for future translational analyses related to recurrence monitoring and molecular characterization of upper tract urothelial carcinoma.
Section:
Peripheral blood samples will be collected at two predefined time points: prior to initiation of neoadjuvant chemotherapy and once between 1-6 months after radical nephroureterectomy.
Plasma-derived circulating tumor DNA (ctDNA) will be analyzed using whole-genome sequencing-based copy number variation assessment to estimate tumor fraction.
Biospecimens are collected for research purposes only and will not be used to guide clinical decision-making.
Samples may be stored for future translational analyses related to recurrence monitoring and molecular characterization of upper tract urothelial carcinoma.